Navigation Links
OGI and MaRS Innovation invest in peptide therapeutics
Date:9/28/2011

Peptides and proteins have long been an attractive class of drug candidates because of their natural involvement in cellular processes and fewer potential side effects. Dr. Andrei Yudin, Professor, Department of Chemistry, University of Toronto, has developed a new and effective process that makes linear peptides circular, which allows these molecules, called macrocycles, to enter cells more effectively and increase their stability compared to linear peptides. Given their advantageous properties, macrocycles are emerging as a new class of molecules with potential in drug development.

Dr. Yudin and his group's unique ability to efficiently cyclize a broad range of linear peptides provides the opportunity to build a diverse library of macrocycles as possible drug candidates. The Yudin group will build a targeted library of macrocyles and test it for important properties including cell permeability and stability. This compound library will enable researchers and pharmaceutical organizations to screen for biologically active structures against disease-relevant targets, with the ultimate goal of identifying novel therapeutic macrocycles for new drug development. Dr. Yudin will be working closely with pharmaceutical companies to build a library that will meet the needs of industry.

"This work has the potential to help change the face of drug development and expand the options available in the creation of new therapeutics," commented Dr. Mark Poznansky, President and CEO, OGI. "Dr. Yudin and his group are clearly poised to be key influencers in this area."

"We are delighted to receive the investment from OGI as we move closer to commercialization," commented Dr. Yudin. "Our initial endeavour to generate a library of compounds is based around fundamental properties of drug-like compounds. Our method of cyclizing peptides will allow us to grow our inventory of compounds to eventually compete on a global scale in this emerging area of constrained peptides."

In addition to the PBDF funding, the technology has received investment by MaRS Innovation, the commercialization agent for 16 Ontario-based research institutions.

"We see significant appetite in the market for viable discovery platforms for peptide based therapeutics. It is important that Dr. Yudin receives appropriate support at this early stage to maximize the potential of this work," commented Dr. Rafi Hofstein, President and CEO, MaRS Innovation. "At MaRS Innovation, we work with many of the Province's leading researchers to convert great science into commercial opportunities."

U of T's Innovations and Partnerships Office (IPO) is working in collaboration with MI and Dr. Yudin to commercialize his novel platform technology.

"The University of Toronto is grateful to the Ontario Genomics Institute for this investment in our research," said Dr. Peter Lewis, Associate Vice President, Research at U of T and Acting Assistant Vice President, IPO. "The PBDF award will be vital in helping U of T and MaRS Innovation to bring Dr. Yudin's innovation to the marketplace. Just as importantly, OGI's support will assist greatly in enabling Dr. Yudin's work to make a strong and positive impact on global society."


'/>"/>

Contact: Alastair Harris-Cartwright
aharriscartwright@ontariogenomics.ca
416-673-6582
Ontario Genomics Institute
Source:Eurekalert

Related medicine news :

1. Austen BioInnovation Institutes Accountable Care Community initiative gains national support
2. BUSM professor honored with Excellence and Innovation in Education and Training Award
3. Innovations in cardiovascular therapies and treatments will be presented at TCT 2011
4. Three senior Hebrew University faculty members receive Kaye Awards for innovations
5. QB3, Deloitte collaborate to drive California bioscience innovation
6. Innovation in science
7. Sones Innovation Award honors breast cancer vaccine research
8. Student innovation at Rensselaer Polytechnic Institute could lead to better breast cancer screening
9. ACP applauds President Obamas call for state innovation on health insurance coverage
10. How do data exclusivity periods affect pharmaceutical innovation?
11. SNM sharpens focus on molecular imaging innovation and translation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... ... disabilities, it is so critically important that we all are aware of our ... why Mediaplanet is proud to announce the launch of its newest edition of ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Yisrayl Hawkins, ... focuses on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement ... current generation. He explains that the Bible details the current times so plainly ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to Head ... division on February 12th. Ms. Esparza qualified into this prestigious status after ... held in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts in ...
(Date:2/23/2017)... FL (PRWEB) , ... February 23, 2017 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – will return to the La Gorce Country Club in Miami Beach to ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... in thought leadership , media relations, content marketing, social media management, corporate ... several clients already in the state and in nearby New Hampshire, Massachusetts and ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... and Strategies - 2016" report to their offering. ... The latest research Autism ... pricing data and benchmarks in the global Autism Spectrum Disorder market. ... What are the key drugs marketed for Autism Spectrum Disorder ...
(Date:2/23/2017)... -- ITL Limited, ( ASX: ITD ), an innovative diversified healthcare ... ended 31 December 2016 compared with the previous corresponding period. A ... here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: 1.2 ... $15.7m; up 11%) Profit before tax of $2.12m ...
(Date:2/23/2017)... Research and Markets has announced the addition ... 2016" report to their offering. ... The latest research Oesophageal Cancer Drugs Price ... in the global Oesophageal Cancer market. The research answers ... key drugs marketed for Oesophageal Cancer and their clinical attributes? How ...
Breaking Medicine Technology: